SCHEMBL12878663

SCHEMBL12878663

CC1CCN(S(=O)(=O)c2ccc3c(c2)cc(C(=O)O)n3S)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.55
▸ MCOLN3 Q8TDD5 1/20 0.55
▸ KMT2A Q03164 6/20 0.50
▸ MEN1 O00255 5/20 0.50
▸ HPGD P15428 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ XBP1 P17861 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ HSD17B10 Q99714 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13744055 0.87 LMNA (0.51) LMNAMCOLN3KMT2AMEN1HPGD
SCHEMBL12878675 0.86 POLB (0.52) LMNAKMT2AMEN1HPGDKDM4E
SCHEMBL10293252 0.85 TSHR (0.53) LMNAMCOLN3TDP1MAPTHSD17B10
SCHEMBL1156404 0.83 LMNA (0.58) LMNAMCOLN3KMT2AMEN1HPGD
SCHEMBL12878927 0.77 HPGD (0.59) LMNAMCOLN3KMT2AMEN1HPGD
SCHEMBL12878661 0.77 MCOLN3 (0.61) LMNAMCOLN3KMT2AMEN1HPGD
SCHEMBL1156115 0.76 LMNA (0.51) LMNAMCOLN3KMT2AMEN1MAPT
SCHEMBL8278538 0.75 LMNA (0.53) LMNAMCOLN3KMT2AMEN1KDM4E
SCHEMBL12878372 0.74 NPSR1 (0.55) LMNAKMT2AMEN1KDM4EHTT
SCHEMBL10293336 0.74 LMNA (0.52) LMNAMCOLN3KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 — — US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 — — US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C LMNA 1753/4885MCOLN3 431/4885KMT2A 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback